Back to Results
First PageMeta Content
Pharmaceuticals policy / Pharmaceutical industry / Food and Drug Administration / Drug discovery / Generic drug / Drug Price Competition and Patent Term Restoration Act / Pharmaceutical marketing / Drug development / Clinical trial / Pharmaceutical sciences / Pharmacology / Health


Document Date: 2003-04-25 10:53:02

Open Document

File Size: 208,41 KB

Share Result on Facebook

City

Cincinnati / Philadelphia / Portland / Washington / Boston / Cambridge / /

Company

Novartis / Amgen / GlaxoSmithKline / Merck / The New York Times / The New England Journal / Burroughs Wellcome Co. / Pfizer / Public Citizen / Dole / /

Continent

America / /

Country

Israel / United States / Columbia / /

Currency

USD / /

Event

FDA Phase / Person Communication and Meetings / Patent Issuance / /

Facility

Columbia University / Duke University / University of Rochester Graduate School / Oregon Health Sciences University / Tufts Center / University of Chicago / Tufts University / /

IndustryTerm

treatment of kidney failure / brand-name pharmaceuticals / pharmaceutical industry / biotechnology industries / generic product / pharmaceutical innovation / chemical entities / manufacturing / advertising enterprise / pharmaceutical accounts / debatable accounting theory / biotechnology / profitable new products / definitive chemical identification / cancer treatment / treatment of other cancers / insurance plans / marketed drug products / pharmaceutical / treatment of a type of blood cancer / individual pharmaceutical firms / consumer watch / telephone conversations / pharmaceutical giant / treatment of AIDS / advertising money / public relations / treatment for cancer / pharmaceutical firms / /

MedicalCondition

arthritis / chronic kidney disease / blood cancer / leukemia / cancer / allergy / kidney failure / diseases / AIDS / high blood pressure / depression / experimental viral infections / severe anemia / hay fever / HIV infection / cancers / acute diseases / disease / erectile dysfunction / heart failure / chronic myeloid leukemia / anemia / /

MedicalTreatment

combination drug therapy / drug therapy / /

Organization

Columbia University / Oregon Health Sciences University / Department of Economics / U.S. government / state medical society / Michigan Cancer Foundation / office of the Inspector General / University of Rochester Graduate School / Medicare / Duke University / Association of American Medical Colleges / Pharmaceutical Research and Manufacturers of America / FDA / Securities and Exchange Commission / Harvard Medical School / National Institute of Health / Food and Drug Administration / MIT / Tufts University / national professional organization / Congress / American Medical Student Association / the University of Chicago / American Medical Association / Department of Health and Human Services / Tufts Center for the Study of Drug Development / Office for Technology Assessment / /

Person

Marcia Angell / KEN ORVIDAS / Joseph DiMasi / Brian J. Druker / Raymond V. Gilmartin / Bill Moyers / Arnold S. Relman / /

Position

physician / professor emeritus / influential chairman and CEO / senior author / senior lecturer / speaker / consultant / scientist / candidate drug / editor-in-chief / clinical research physician / professor emeritus of medicine and social medicine / /

Product

Gleevec / Retrovir / Capoten / Zovirax / Zantac / Zidovudine / Prozac / Vasotec / newly approved drug / Other Drug / drug / /

ProvinceOrState

Massachusetts / /

PublishedMedium

The New York Times / THE NEW REPUBLIC / The New England Journal of Medicine / /

Technology

biotechnology / Drug Development / /

SocialTag